
JELMYTO® Shows Impressive 86% Recurrence-Free Survival (RFS) at 24 Months Across Varied Patient Profiles: Insights from AUA 2024 Retrospective Analysis
UroGen Pharma Ltd. (Nasdaq: URGN) has unveiled significant findings from a sub-analysis within the largest real-world patient cohort evaluation of JELMYTO (mitomycin) for pyelocalyceal solution, presented at the American Urological Association Meeting 2024 in San Antonio, TX. This analysis focused…